Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Blood (2024) 144 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2024-201944

Published: 2024

Journal Articles

FVIII and VWF PK: Key Aspects in Safety and Efficiency of VWF Concentrates. Review and Reflection

Manuel Rodriguez-Lopez, Sr., Ramiro Nuñez Vazquez, Elsa Lopez Ansoar, Miguel Blanquer Blanquer, Carmen Albo Lopez

Blood (2024) 144 (Supplement 1): 5499.

https://doi.org/10.1182/blood-2024-194672

Published: 2024

Journal Articles

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Lucía Pérez-Lamas, Adrian Segura Diaz, Regina García Delgado, Alberto Alvarez-Larran, María Alicia Senin, Elvira Mora, Maria Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raul Perez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo Lopez, Pablo Lorente Alegre, Míriam Vara, Juan Antonio Juan Vera Goñi, Dunia De Miguel Llorente, Angeles Fernández Rodríguez, Alberto Marin Sanchez, Adriana Hernando Megido, Maria Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Perez Encinas, Raquel Mata Serna, Lucia Nuñez Martin-Buitrago, Francisca Ferrer Marin, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, Maria José Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Angela Martinez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, Maria Isabel Mata Vazquez, Inmaculada Castillo Valero, Maria Jose Fernández, Carlos Aguilar, Marta Santaliestra, Antonio Garcia Menchon, Begona Navas Elorza, Maria Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Mª Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, María José Llácer Ferrandis, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jimenez Barcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía Delapuerta, Alvaro Lorenzo Vizcaya, Juan Carlos Hernandez Boluda, Valentín García Gutiérrez, Sr.

Blood (2024) 144 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2024-200698

Published: 2024

Journal Articles

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Blood (2023) 142 (Supplement 1): 4899.

https://doi.org/10.1182/blood-2023-181815

Published: 2023

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Journal Articles

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Blood (2019) 134 (Supplement_1): 2405.

https://doi.org/10.1182/blood-2019-127946

Published: 2019

Journal Articles

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Blood (2019) 134 (Supplement_1): 4171.

https://doi.org/10.1182/blood-2019-126980

Published: 2019

Journal Articles

Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry

Blood (2016) 128 (22): 3451.

https://doi.org/10.1182/blood.V128.22.3451.3451

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Blood (2016) 128 (22): 4201.

https://doi.org/10.1182/blood.V128.22.4201.4201

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Blood (2015) 126 (23): 1514.

https://doi.org/10.1182/blood.V126.23.1514.1514

Published: 2015

Journal Articles

Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients

Blood (2015) 126 (23): 521.

https://doi.org/10.1182/blood.V126.23.521.521

Published: 2015

Journal Articles

High Dose Therapy with Autologous Stem Cell Transplantation (HDT/ASCT) Support in Follicular Lymphoma (FL) a Very Long Follow-up Analysis of 640 Patients of Geltamo Spanish Group Suggests That FL Might be Cured, Even in High-Risk Patients

Blood (2014) 124 (21): 675.

https://doi.org/10.1182/blood.V124.21.675.675

Published: 2014

Journal Articles

Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HCT) In Patients With Relapsed Or Refractory Acute Leukemia

Josefina Serrano, Diana Buenasmañanas, P Herrera, Mari Luz Amigo, Marisa Calabuig, Eusebio Martin, PhD, Maria-Belén Vidriales, Adolfo de la Fuente, M Santero, Silvia Negri, Jose Gonzalez-Campos, Carmen Albo, Sonia Gonzalez, Jose J. Rifon, MD, M Cruz Viguria, V Garcia-Gutierrez, Carmen Martin, Joaquin Sanchez-Garcia

Blood (2013) 122 (21): 3410.

https://doi.org/10.1182/blood.V122.21.3410.3410

Published: 2013

Journal Articles

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Blood (2013) 122 (8): 1448–1454.

https://doi.org/10.1182/blood-2013-02-483420

Published: 2013

Includes: Supplemental data

Journal Articles

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Blood (2012) 120 (21): 2680.

https://doi.org/10.1182/blood.V120.21.2680.2680

Published: 2012

Journal Articles

Front-Line Autologous Stem Cell Transplantation (ASCT) in Primary Mediastinal Large B-Cell Lymphoma: The GEL-TAMO Experience.

Jose Rodriguez, Eulogio Conde, Antonio Gutierrez, Juan Carlos Garcia-Ruiz, Juan Jose Lahuerta, Maria Rosario Varela, Encarnacion Perez-Equiza, Julian Marin, Carmen Albo, Maria Dolores Caballero

Blood (2006) 108 (11): 3056.

https://doi.org/10.1182/blood.V108.11.3056.3056

Published: 2006

Journal Articles

Front-Line Consolidation with Autologous Stem Cell Transplantation in Patients with Nodal Aggressive Peripheral T-Cell Lymphoma (PTCL). A Prospective Study of the GEL-TAMO.

Jose Rodriguez, MD, Eulogio Conde, MD, Antonio Gutierrez, MD, Reyes Arranz, MD, Angel Leon, MD, Julian Marin, MD, Maurizio Bendandi, MD, Carmen Albo, MD, Maria Dolores Caballero, MD

Blood (2006) 108 (11): 2463.

https://doi.org/10.1182/blood.V108.11.2463.2463

Published: 2006

Journal Articles

Treatment Stratification According to Early Response to Mega-CHOP, Based on CT and Gallium 67 Scan (G 67 S) with or without IFE Salvage Therapy Followed by Peripheral Autologous Stem Cell Transplant (PBSCT) in Patient with Poor Prognosis Aggressive Lymphoma. A Preliminary Report from a Prospective GEL/TAMO Trial.

Eulogio Conde, MD, Reyes Arranz, José Rodriguez, María L. Gutierrez, Carlos Grande, Marco Gandarillas, Carmen Albo, José L. Bello, Sebastián Garzón, Miguel T. Hernández, José A. García-Vela, Pascual Fernández, María L. Amigo, Dolores Caballero

Blood (2005) 106 (11): 3335.

https://doi.org/10.1182/blood.V106.11.3335.3335

Published: 2005

Journal Articles

Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.

Blood (2005) 106 (11): 2082.

https://doi.org/10.1182/blood.V106.11.2082.2082

Published: 2005

NARROW

Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

FVIII and VWF PK: Key Aspects in Safety and Efficiency of VWF Concentrates. Review and Reflection

Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Bispecific T-Cell Engagers for B-Cell NON-Hodgkin Lymphoma Patients before Allogeneic Stem Cell Transplantation. a Study on Behalf Od Geth-TC

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Incidence and Prognostic Impact of Secondary Neoplasia after High Dose Therapy Supported By Autologous Stem Cell Transplantation in Follicular Lymphoma. a Long Term Follow-up Analysis from the Geltamo Registry

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamicine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis

Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients

High Dose Therapy with Autologous Stem Cell Transplantation (HDT/ASCT) Support in Follicular Lymphoma (FL) a Very Long Follow-up Analysis of 640 Patients of Geltamo Spanish Group Suggests That FL Might be Cured, Even in High-Risk Patients

Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HCT) In Patients With Relapsed Or Refractory Acute Leukemia

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Front-Line Autologous Stem Cell Transplantation (ASCT) in Primary Mediastinal Large B-Cell Lymphoma: The GEL-TAMO Experience.

Front-Line Consolidation with Autologous Stem Cell Transplantation in Patients with Nodal Aggressive Peripheral T-Cell Lymphoma (PTCL). A Prospective Study of the GEL-TAMO.

Prolonged Survival in Patients with Angioimmunoblastic T-Cell Lymphoma (AIL) after High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). The GELTAMO Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only